232 related articles for article (PubMed ID: 21904385)
1. Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome.
Krejsgaard T; Odum N; Geisler C; Wasik MA; Woetmann A
Leukemia; 2012 Mar; 26(3):424-32. PubMed ID: 21904385
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
3. CD4⁺CD25⁺FOXP3⁺ malignant T cells in Sézary syndrome are not necessarily functional regulatory T cells.
Wada DA; Pittelkow MR; Comfere NI; Gibson LE; Ansell SM; Wilcox RA
J Am Acad Dermatol; 2013 Sep; 69(3):485-9. PubMed ID: 23957976
[No Abstract] [Full Text] [Related]
4. The regulatory T-cell phenotype in progressive mycosis fungoides.
Hallermann C; Schulze HJ; Neumann C; Klemke CD
G Ital Dermatol Venereol; 2008 Feb; 143(1):15-9. PubMed ID: 18833048
[TBL] [Abstract][Full Text] [Related]
5. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
6. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
7. Immunopathogenesis of mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma).
Wong HK
G Ital Dermatol Venereol; 2008 Dec; 143(6):375-83. PubMed ID: 19169210
[TBL] [Abstract][Full Text] [Related]
8. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
[TBL] [Abstract][Full Text] [Related]
9. Mycosis fungoides/Sézary syndrome: report of an unusual case.
Mehta A; Dhungel BM; Khan MF
J Cutan Pathol; 2006 Sep; 33 Suppl 2():12-5. PubMed ID: 16972946
[TBL] [Abstract][Full Text] [Related]
10. Profiles of Foxp3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides.
Fujimura T; Okuyama R; Ito Y; Aiba S
Br J Dermatol; 2008 Jun; 158(6):1256-63. PubMed ID: 18363755
[TBL] [Abstract][Full Text] [Related]
11. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
12. Killer cell immunoglobulin-like receptor expression delineates in situ Sézary syndrome lymphocytes.
Wechsler J; Bagot M; Nikolova M; Parolini S; Martin-Garcia N; Boumsell L; Moretta A; Bensussan A
J Pathol; 2003 Jan; 199(1):77-83. PubMed ID: 12474229
[TBL] [Abstract][Full Text] [Related]
13. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).
Shalabi D; Bistline A; Alpdogan O; Kartan S; Mishra A; Porcu P; Nikbakht N
Chin Clin Oncol; 2019 Feb; 8(1):11. PubMed ID: 30691274
[TBL] [Abstract][Full Text] [Related]
14. Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides.
Haynes BF; Bunn P; Mann D; Thomas C; Eisenbarth GS; Minna J; Fauci AS
J Clin Invest; 1981 Feb; 67(2):523-30. PubMed ID: 6970206
[TBL] [Abstract][Full Text] [Related]
15. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome).
Cirée A; Michel L; Camilleri-Bröet S; Jean Louis F; Oster M; Flageul B; Senet P; Fossiez F; Fridman WH; Bachelez H; Tartour E
Int J Cancer; 2004 Oct; 112(1):113-20. PubMed ID: 15305382
[TBL] [Abstract][Full Text] [Related]
16. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions.
Doherty SD; Ni X; Doherty CB; Jones D; Zhao X; Owen LB; Duvic M
Arch Dermatol Res; 2006 Dec; 298(7):353-6. PubMed ID: 17021762
[TBL] [Abstract][Full Text] [Related]
17. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
18. Immunopathology of cutaneous T-cell lymphomas.
Nasu K; Said J; Vonderheid E; Olerud J; Sako D; Kadin M
Am J Pathol; 1985 Jun; 119(3):436-47. PubMed ID: 3893149
[TBL] [Abstract][Full Text] [Related]
19. FOXP3 in sequential biopsies of progressive mycosis fungoides.
Fried I; Cerroni L
Am J Dermatopathol; 2012 May; 34(3):263-5. PubMed ID: 22157245
[TBL] [Abstract][Full Text] [Related]
20. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
